fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Metronidazole

All products: general benefit

Mint-Metronidazole · DIN 02535807 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Mint-Metronidazole · DIN 02535807 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-10-31 Daily cost (source): $0.1716 Health Canada: Marketed since 2023-09-07 · brand MINT-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Tablet · route Oral · ingredients METRONIDAZOLE 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Metronidazole: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0572). What the ministry pays, not the patient.

Ministry pays: $0.0572 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02535807)

Source record
DIN 02535807: Mint-Metronidazole Raw flags: sec3=Y Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id MIN Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.0572; ministry $0.0572 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02535807 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102463
Interchangeable products
Apo-Metronidazole Tablets · DIN 00545066 · $0.0572 Flagyl · DIN 01926896 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535807
Shortage record checked October 6, 2026
Other drugs in the same formulary class (08:32 Trichomonacides) and how they are covered
No products matched this class search: “08:32”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for: Bacterial Vaginosis Metronidazole is indicated for the treatment of bacterial vaginosis. Protozoal Infections • Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas vaginalis). • Hepatic and intestinal amebiasis. • Giardiasis. Bacterial Infections Treatment: Culture and susceptibility studies should be performed to determine the causative organisms and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological findings, therapy may be started while awaiting the results of these tests. However, modification of the treatment may be necessary once these results become available. In mixed aerobic and anaerobic infections, consideration should be given to the concomitant administration of an antibiotic appropriate for the treatment of the aerobic component of the infection. See 7 Warnings and Precautions, General. Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections (some with abscesses) caused by anaerobic bacteria. Prophylaxis: If there are signs of infections, spe… https://pdf.hres.ca/dpd_pm/00084527.PDF PM date: 2026-04-20 Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.